ARCHIVES

Satraplatin Improved PFS In Refractory Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 26 No. 7 | July 25, 2003

Download PDF Visit The Full Archive

Related Articles

Early-Stage HER2+ Breast Cancer Patients Are At Significant Risk Of Recurrence

December 26, 2008

NIH Inquiry Finds No Impropriety In Treatment of Teddy DeVita

April 9, 1976

House Committee Approves $1.9 Bil. NCI Budget

July 31, 1992

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

July 25, 2014

RFA For Patterns Of Care Studies Announced By DCCR

November 10, 1978